BORA PHARMACEUTICALS LTD Asset Resilience Ratio
BORA PHARMACEUTICALS LTD asset resilience ratio. BORA PHARMACEUTICALS LTD (6472) has an Asset Resilience Ratio of 0.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BORA PHARMACEUTICALS LTD defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BORA PHARMACEUTICALS LTD (2019–2025)
Asset resilience ratio of BORA PHARMACEUTICALS LTD from 2019 to 2025. This chart shows how BORA PHARMACEUTICALS LTD's Asset Resilience Ratio has changed over time. Read BORA PHARMACEUTICALS LTD total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BORA PHARMACEUTICALS LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of BORA PHARMACEUTICALS LTD.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$19.02 Million | 0.04% |
| Total Liquid Assets | NT$19.02 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: BORA PHARMACEUTICALS LTD maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BORA PHARMACEUTICALS LTD Industry Peers by Asset Resilience Ratio
Compare BORA PHARMACEUTICALS LTD's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
BORA PHARMACEUTICALS LTD Asset Resilience Ratio by Year (2019–2025)
BORA PHARMACEUTICALS LTD asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for BORA PHARMACEUTICALS LTD.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 0.05% | NT$21.55 Million ≈ $679.04K |
NT$44.71 Billion ≈ $1.41 Billion |
-0.15pp |
| 2024-09-30 | 0.20% | NT$92.34 Million ≈ $2.91 Million |
NT$45.60 Billion ≈ $1.44 Billion |
-1.17pp |
| 2023-09-30 | 1.37% | NT$342.63 Million ≈ $10.79 Million |
NT$25.05 Billion ≈ $789.28 Million |
+0.28pp |
| 2022-09-30 | 1.09% | NT$247.63 Million ≈ $7.80 Million |
NT$22.76 Billion ≈ $717.10 Million |
+1.09pp |
| 2021-09-30 | 0.00% | NT$78.00K ≈ $2.46K |
NT$7.37 Billion ≈ $232.27 Million |
+0.00pp |
| 2020-09-30 | 0.00% | NT$64.00K ≈ $2.02K |
NT$7.00 Billion ≈ $220.67 Million |
-0.89pp |
| 2019-09-30 | 0.89% | NT$30.00 Million ≈ $945.16K |
NT$3.38 Billion ≈ $106.57 Million |
-- |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more